We at TIEFEENBACHER PHARMACEUTICALS strive to make our high-quality medicines better affordable and better available for patients around the world. That´s why we are happy to share that we have successfully prepared the launch of the generic version of Teriflunomide for a market entry on day one after patent expiration in Canada.
Teriflunomide is used to improve the life of patients suffering from Multiple Sclerosis – a chronic disease that effects the central nervous system. The 14 mg film coated tablets are developed and produced in TIEFENBACHER GROUPs own site in India and will be marketed in Canada by our partners, two well-known generic pharmaceutical companies. Our product has already been launched in time in Australia before – a launch in further international markets will follow as soon as the patents of the originator product expire. With this early market entry TIEFENBACHER PHARMACEUTICALS achieves nameable savings for the international health care systems and enables millions of patients a better affordable access to a life-improving treatment.
For further information about our pharmaceuticals or medical devices please contact TIEFENBACHER PHARMACEUTICALS: info@aet.eu
TIEFENBACHER PHARMACEUTICALS is as a part of TIEFENBACHER GROUP – pioneering healthcare since 1963. Please visit us on: www.aet.eu and www.tiefenbachergroup.com
